Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test.[L3335]
Synonyms
Binimetinib
Brand Names
Mektovi
Indication
Binimetinib, in conjunction with encorafenib, is indicated for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutation and metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation.[L48606]
Categories
Antineoplastic Agents
Antineoplastic and Immunomodulating Agents
BCRP/ABCG2 Substrates
Cytochrome P-450 CYP1A2 Substrates
Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index
Cytochrome P-450 CYP2C19 Substrates
Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index
Cytochrome P-450 Substrates
Heterocyclic Compounds, Fused-Ring
Kinase Inhibitor
MAP Kinase Kinase 1, antagonists & inhibitors
MAP Kinase Kinase 2, antagonists & inhibitors
Mitogen-activated protein kinase (MEK) inhibitors
Narrow Therapeutic Index Drugs
P-glycoprotein substrates
P-glycoprotein substrates with a Narrow Therapeutic Index
Protein Kinase Inhibitors
UGT1A1 Substrates
UGT1A1 Substrates with a Narrow Therapeutic Index
ATC-Code
L01EE03
CAS number
606143-89-9
Drug Targets
Name
Target Sequence
Pharmacological Action
Actions
Dual specificity mitogen-activated protein kinase kinase 2
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
